Depomed, Inc announced a product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 (formerly Gabapentin GR) for the treatment of pain in the United States, Canada, Mexico and Puerto Rico.
The details can be read here.
No comments:
Post a Comment